CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Padagis LLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Padagis LLC
1251 Lincoln Road
Allegan, MI  49010  United States

This company was Merged or Acquired on 7/6/2021.
This is a Subsidiary, click here for the Parent Company

Business Summary
Padagis LLC develops, manufactures, and markets a portfolio of generic Rx and OTC products. The Company's products include prescription creams, ointments, suspensions, gels, foams, sprays, patches, nasal, and suppositories. It specializes in manufacturing items that involve challenging branded pharmaceutical patents. The Company is the former generic prescription pharmaceuticals business of Perrigo Company plc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
---YesYesYes-

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
--Yes----

Business Names
Business Name
Agis Industries Paddock Laboratories
Padagis, LLC


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 2, 2024